CBG and anxiety: the measure matters

The randomized crossover field trial included 34 cannabis-experienced adults, not an anxiety-disorder treatment population. Its hemp-derived CBG tincture also contained CBGA and terpenoids. Early remote observations do not cover other mixtures, new users or repeated use.

Single-item subjective anxiety favored CBG. Multi-item STAI-state had no significant overall condition effect; its condition-by-time interaction was nominally significant, but individual time-point contrasts were not. Neither “all measures improved” nor “all were null” describes these findings.

Comparisons lacked multiplicity correction. Mood and DRUID task results were nonsignificant. Nominal signals need replication; a nonsignificant impairment task does not establish safety or driving permission.

Selected symptom ratings showed no significant condition differences. There were no open-ended adverse-event questions, physical exams or vital signs; people with prior serious CBG reactions were excluded. Later, repeated-use and rare harms remain unassessed.

CReDO Science funded the study; Shango Los donated tincture. Authors disclosed cannabis-industry relationships, including funder leadership. Disclosures alone neither prove nor disprove results.